BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 26678957)

  • 1. Urachal Carcinoma of the Bladder: Impact of Clinical and Immunohistochemical Parameters on Prognosis.
    Niedworok C; Panitz M; Szarvas T; Reis H; Reis AC; Szendröi A; Nyirády P; Szasz AM; Módos O; Rübben H; Vom Dorp F
    J Urol; 2016 Jun; 195(6):1690-6. PubMed ID: 26678957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder.
    Sitnikova L; Mendese G; Liu Q; Woda BA; Lu D; Dresser K; Mohanty S; Rock KL; Jiang Z
    Clin Cancer Res; 2008 Mar; 14(6):1701-6. PubMed ID: 18347170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder.
    Xylinas E; Cha EK; Khani F; Kluth LA; Rieken M; Volkmer BG; Hautmann R; Küfer R; Chen YT; Zerbib M; Rubin MA; Scherr DS; Shariat SF; Robinson BD
    J Urol; 2014 Mar; 191(3):830-41. PubMed ID: 23994370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder.
    Yurakh AO; Ramos D; Calabuig-Fariñas S; López-Guerrero JA; Rubio J; Solsona E; Romanenko AM; Vozianov AF; Pellin A; Llombart-Bosch A
    Eur Urol; 2006 Sep; 50(3):506-15; discussion 515. PubMed ID: 16624482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation.
    Gopalan A; Sharp DS; Fine SW; Tickoo SK; Herr HW; Reuter VE; Olgac S
    Am J Surg Pathol; 2009 May; 33(5):659-68. PubMed ID: 19252435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of topoisomerase II alpha, ki67, and p53 in primary non-muscle-invasive urothelial bladder carcinoma.
    Ben Abdelkrim S; Rammeh S; Ziadi S; Tlili T; Jaidane M; Mokni M
    J Immunoassay Immunochem; 2014; 35(4):358-67. PubMed ID: 24624938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of the receptor of hyaluronan-mediated motility (RHAMM) on human urothelial transitional cell cancer of the bladder.
    Niedworok C; Kretschmer I; Röck K; Vom Dorp F; Szarvas T; Heß J; Freudenberger T; Melchior-Becker A; Rübben H; Fischer JW
    PLoS One; 2013; 8(9):e75681. PubMed ID: 24069434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anterior wall adenocarcinoma of bladder with similar clinicopathological and prognostic characteristics as common bladder carcinomas should not be treated as or classified into urachal adenocarcinomas.
    Zhou YW; Long YX; Song K; Liang LB; Cheng K; Chen Y; Liu JY
    Cancer Med; 2021 Aug; 10(16):5415-5428. PubMed ID: 34278741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IMP3 expression in urothelial carcinomas of the urinary bladder.
    Ozdemir NO; Türk NS; Düzcan E
    Turk Patoloji Derg; 2011 Jan; 27(1):31-7. PubMed ID: 21469424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urachal carcinomas of the nonglandular type: salient features and considerations in pathologic diagnosis.
    Paner GP; Barkan GA; Mehta V; Sirintrapun SJ; Tsuzuki T; Sebo TJ; Jimenez RE
    Am J Surg Pathol; 2012 Mar; 36(3):432-42. PubMed ID: 22301493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of E-cadherin, Ki-67, and p53 in urinary bladder cancer in relation to progression, survival, and recurrence.
    Ziaran S; Harsanyi S; Bevizova K; Varchulova Novakova Z; Trebaticky B; Bujdak P; Galbavy S; Danisovic L
    Eur J Histochem; 2020 Mar; 64(2):. PubMed ID: 32214283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma.
    Rodríguez-Alonso A; Pita-Fernández S; González-Carreró J; Nogueira-March JL
    Eur Urol; 2002 Feb; 41(2):182-8; discussion 188-9. PubMed ID: 12074407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review and meta-analysis of CK20, CD44, Ki67 and p53 as immunohistochemical markers in bladder carcinoma in situ.
    Straccia P; Fiorentino V; Martini M; Pierconti F
    Actas Urol Esp (Engl Ed); 2022 Nov; 46(9):521-530. PubMed ID: 36216762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IMP3 is a biomarker for non-muscle-invasive urothelial carcinoma of the bladder associated with an aggressive phenotype.
    Yang F; Zhou Q; Meng L; Xing N
    Medicine (Baltimore); 2019 Jul; 98(27):e16009. PubMed ID: 31277094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification.
    Santos L; Amaro T; Costa C; Pereira S; Bento MJ; Lopes P; Oliveira J; Criado B; Lopes C
    Int J Cancer; 2003 Jun; 105(2):267-72. PubMed ID: 12673690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder.
    Moonen L; Ong F; Gallee M; Verheij M; Horenblas S; Hart AA; Bartelink H
    Int J Radiat Oncol Biol Phys; 2001 Apr; 49(5):1305-10. PubMed ID: 11286838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens.
    Tsuji M; Kojima K; Murakami Y; Kanayama H; Kagawa S
    Br J Urol; 1997 Mar; 79(3):367-72. PubMed ID: 9117215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
    Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
    Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.